Publication | Closed Access
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
181
Citations
26
References
2004
Year
Trastuzumab (Herceptin) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC.
| Year | Citations | |
|---|---|---|
Page 1
Page 1